| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | Oct 2, 2025 | VYNE Therapeutics Inc. | CFO | Sell | 47.5 | -3,420 | -2.97% | ✗ | $1.1K |
| Jun 30, 2025 | Jul 2, 2025 | VYNE Therapeutics Inc. | CFO | Sell | 47.5 | -3,420 | -2.89% | ✗ | $5.6K |
| Mar 31, 2025 | Apr 2, 2025 | VYNE Therapeutics Inc. | CFO | Sell | 46.3 | -8,399 | -6.62% | ✗ | $13.3K |
| Dec 31, 2024 | Jan 2, 2025 | VYNE Therapeutics Inc. | CFO | Sell | 46.3 | -4,675 | -3.55% | ✗ | $15.7K |
| Sep 30, 2024 | Oct 2, 2024 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -84 | -0.06% | ✗ | $157.9 |
| Jul 1, 2024 | Jul 3, 2024 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -92 | -0.07% | ✗ | $176.6 |
| Apr 1, 2024 | Apr 3, 2024 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -94 | -0.07% | ✗ | $289.5 |
| Jan 1, 2024 | Jan 3, 2024 | VYNE Therapeutics Inc. | CFO | Sell | 90.0 | +62,407 | 89.88% | ✗ | $212 |
| Oct 2, 2023 | Oct 4, 2023 | VYNE Therapeutics Inc. | CFO | Sell | 47.5 | -1,087 | -13.56% | ✗ | $4.2K |
| Jun 30, 2023 | Jul 5, 2023 | VYNE Therapeutics Inc. | CFO | Sell | 47.5 | -91 | -1.12% | ✗ | $373.1 |
| Mar 31, 2023 | Apr 4, 2023 | VYNE Therapeutics Inc. | CFO | Sell | 47.5 | -384 | -4.52% | ✗ | $1.2K |
| Dec 31, 2022 | Jan 4, 2023 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -354 | -0.20% | ✗ | $53.1 |
| Sep 30, 2022 | Oct 4, 2022 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -353 | -0.20% | ✗ | $78.7 |
| Jun 30, 2022 | Jul 5, 2022 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -354 | -0.20% | ✗ | $137.7 |
| Mar 31, 2022 | Apr 4, 2022 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -773 | -0.48% | ✗ | $502.5 |
| Dec 31, 2021 | Jan 4, 2022 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -206 | -0.24% | ✗ | $210.1 |
| Sep 30, 2021 | Oct 1, 2021 | VYNE Therapeutics Inc. | CFO | Sell | 52.5 | -206 | -0.25% | ✗ | $286.3 |
| Jun 30, 2021 | Jul 2, 2021 | VYNE Therapeutics Inc. | CFO | Sell | 47.5 | -700 | -2.99% | ✗ | $2.5K |